How Long Is a Respiratory Infection Contagious?

Most respiratory infections are contagious for roughly five to ten days after symptoms begin, though the exact window depends on which virus you have, how your immune system responds, and whether you’ve been vaccinated or treated with antivirals. The contagious period and the period during which you test positive are not the same thing, and confusing the two is one of the most common mistakes people make when deciding when to leave isolation. What follows is a virus-by-virus breakdown and the factors that can push the contagious window shorter or longer than average.

The Contagious Window for Common Respiratory Viruses

The length of time you can spread a respiratory infection hinges on how long your body produces live, replicating virus. That is distinct from how long viral genetic material (RNA) lingers, which can persist well after you’ve stopped being infectious. Studies that use cell cultures to isolate live virus give us the most reliable picture of true contagiousness, and those studies tell a reasonably consistent story across the major respiratory viruses.

For SARS-CoV-2, live virus is rarely recovered after about eight to ten days from symptom onset. A review of virus-culture studies found that the last day infectious virus could be isolated typically fell within ten days of symptoms, with only around three percent of patients shedding culturable virus beyond that point.¹ Peak viral loads tend to hit around the fourth or fifth day of symptoms and decline from there.² Viral RNA, on the other hand, can remain detectable for weeks, which is why a PCR test can stay positive long after you’ve stopped posing a risk to others. A study of the Omicron variant in vaccinated individuals found RNA still detectable ten days after diagnosis, but no live virus could be grown from those samples.³ Specimens collected at least twenty days after diagnosis also failed to produce any live virus in cell culture.⁴

For RSV, the picture is similar in shape but a bit shorter. A human challenge study found that infectious virus appeared about three days after exposure and cleared by about eight days, giving a median shedding duration of five days. Viral RNA lingered considerably longer, clearing around twelve days after exposure.⁵ That said, RSV shedding in young children can last substantially longer than in adults, a pattern we’ll return to below.

For influenza, the contagious period is generally shorter than either SARS-CoV-2 or RSV. Most adults shed live flu virus for about five to seven days from symptom onset, with viral loads peaking in the first two to three days of illness. Children can shed for ten days or more. The shorter infectious window is one reason the flu tends to move through households faster than COVID-19 does, with serial intervals (the time between one person falling ill and the next) averaging just two to three days.

You Can Spread It Before You Feel Sick

One of the trickier aspects of respiratory infections is presymptomatic transmission. You don’t need to be coughing or sneezing to pass a virus along. For SARS-CoV-2, viral shedding has been documented one to two days before symptoms appear, though the viral loads at that early stage tend to be moderate rather than at their peak.⁶ This presymptomatic shedding is a big part of why COVID-19 proved so difficult to contain with symptom-based screening alone.

Influenza shows a similar pattern but with interesting individual variation. A multi-season household study estimated that most people shed less than ten percent of their total virus before their first symptoms appeared. However, about fifteen percent of infected individuals shed more than half their total virus before feeling ill.⁷ So while presymptomatic flu spreading is real, it’s heavily concentrated in a subset of people. You might be the type who sneezes first and sheds later, or you might be the type who’s already broadcasting virus a day before you know you’re sick.

Why Children Stay Contagious Longer

If you’ve ever noticed that a cold seems to burn through an entire daycare over weeks while adults in the same household recover and stop spreading it relatively quickly, there’s a biological reason. Children, especially those under five, tend to shed respiratory viruses for longer than adults. Their immune systems are encountering many of these viruses for the first time, so the process of recognizing, fighting, and clearing the infection simply takes longer.

A household transmission study in Nicaragua found that children under six years old had both a longer presymptomatic shedding period and a longer postsymptomatic shedding period for influenza compared to adults. Children aged six to fifteen fell somewhere in between.⁸ For RSV specifically, modeling work has estimated that an infected child under five is more than twice as likely as a person over fifty to transmit the virus.⁹ That higher transmission probability reflects both the longer shedding window and the behavioral reality that young children are not great at covering their coughs or keeping their hands away from shared surfaces.

This has practical implications if you’re trying to figure out when a sick child can safely return to school or daycare. Standard guidance built around adult shedding timelines may underestimate how long a young child remains contagious. Waiting an extra day or two beyond fever resolution, especially with RSV and flu, is often warranted.

When the Contagious Period Stretches to Weeks or Months

For people with severely weakened immune systems, the normal rules about contagious windows largely go out the window. Where a healthy adult clears live SARS-CoV-2 within about ten days, immunocompromised individuals can remain infectious for dramatically longer. A systematic review found that among immunocompromised patients who had viral cultures performed, the median duration of replication-competent virus was about sixty days from symptom onset, with one patient shedding culturable virus for 238 days.¹⁰ Case reports have described deeply immunocompromised patients shedding infectious virus for several months, with outcomes ranging from asymptomatic carriage to superinfection with a second strain.¹¹

This isn’t just a concern for the patient’s own health. Prolonged infectious shedding in immunocompromised hosts has been flagged as a potential pathway for the evolution of new viral variants, since the virus has more time and more replication cycles in which to accumulate mutations. It also means that standard isolation timelines don’t apply to people on chemotherapy, organ transplant recipients on immunosuppressive drugs, or those with advanced HIV. Healthcare teams managing these patients often rely on repeated viral cultures or antigen tests rather than a calendar-based countdown.¹²

Older Adults and Slower Viral Clearance

Even without overt immunocompromise, aging itself tends to extend the period of viral shedding. A study of hospitalized COVID-19 patients found that older age was independently associated with prolonged viral RNA shedding. The median duration of RNA shedding climbed with each age bracket: about 23 days for patients 40 and under, 30 days for those in their forties, and 34 days for those over 70.¹³ A study of older patients infected with the Omicron variant confirmed the same trend, finding that older age prolonged viral shedding duration.¹⁴

It’s worth noting that RNA shedding duration is not the same as infectious virus duration, as established earlier. But the correlation between age and slower clearance almost certainly translates into at least modestly longer contagious windows for older adults, even if the gap isn’t as dramatic as the RNA numbers suggest. If you’re caring for an elderly family member with a respiratory infection, erring on the side of a longer isolation period is reasonable.

Do Antivirals Shorten the Contagious Window?

Antiviral treatments like Paxlovid (nirmatrelvir/ritonavir) for COVID-19 dramatically suppress viral replication while you’re taking them. Modeling of clinical trial data has estimated that Paxlovid represses viral replication by over 99 percent per day during treatment.¹⁵ For most people, this translates into a faster drop in viral load and, in principle, a shorter period of contagiousness.

There’s a catch, though. Paxlovid works by blocking viral replication, which also preserves the supply of cells the virus hasn’t yet infected. If viable virus remains when treatment ends after the standard five-day course, those preserved cells can support a rebound in viral replication.¹⁶ This “Paxlovid rebound” phenomenon means some people test negative briefly after finishing the drug, then test positive again a few days later. During rebound, they can carry live virus and are presumably contagious again. The rebound is usually mild and self-limited, but it complicates the question of when you can safely declare yourself non-contagious after treatment.

In immunocompromised animal models, late-onset antiviral treatment significantly shortened the duration of persistent virus replication, though Paxlovid-treated animals still showed rebound virus in the upper respiratory tract after treatment ended. Longer treatment courses (fourteen days rather than the standard five) appeared to reduce this rebound effect.¹⁷ For now, the practical takeaway is that antivirals likely shorten the contagious period on average, but rebound means you shouldn’t assume you’re in the clear the moment you finish your pills.

Can a Rapid Test Tell You Whether You’re Still Contagious?

This is one of the most useful practical questions, and the answer is genuinely encouraging. While PCR tests detect viral RNA and can stay positive for weeks after you stop being infectious, rapid antigen tests are a much better proxy for contagiousness. A study comparing antigen test results against viral cultures found that a negative rapid antigen test had a negative predictive value of 99.9 percent for contagiousness, meaning that if the antigen test is negative, you are almost certainly not shedding live virus anymore.¹⁸ A separate evaluation reached the same conclusion: patients with a negative rapid antigen test could be regarded as non-contagious.¹⁹

This gives you a practical tool. If you’ve had COVID-19 and want to know whether you’re safe to be around others, a negative rapid antigen test is a strong signal. A positive PCR at the same stage doesn’t necessarily mean you’re still contagious. For influenza and RSV, rapid antigen tests are less widely studied as contagiousness markers, so calendar-based guidelines (staying home until at least 24 hours fever-free, with symptoms improving) remain the main practical guide.

How Respiratory Viruses Actually Travel Between People

Understanding the contagious window matters more when you understand how the virus gets from one person to the next, because the routes of transmission influence which stages of illness are most dangerous. Respiratory viruses spread through a spectrum of particle sizes. Large droplets (the kind produced by a forceful cough or sneeze) travel a few feet and settle quickly. Smaller aerosol particles (produced even by normal breathing and talking) can hang in the air and travel farther.

Physical modeling of coughing has shown that when a second person is standing about one meter away, their body changes the airflow in a way that actually elevates and extends the droplet plume, engulfing the listener’s head in a cloud of particles that would have otherwise fallen short.²⁰ For influenza specifically, evidence supports aerosol transmission as an important route, modulated by temperature and humidity. Studies have demonstrated that the virus survives well in aerosol suspension and that the infectious dose required via aerosol is quite low.²¹

The practical relevance is that contagiousness isn’t just about whether you’re shedding virus — it’s also about what you’re doing while shedding. Speaking loudly, singing, exercising near others, or being in a poorly ventilated room all amplify transmission risk during your contagious window. Conversely, wearing a well-fitting mask or staying in a well-ventilated space substantially reduces the risk even if you’re still shedding some virus.

Current Isolation Guidance

Public health guidance on isolation has evolved considerably since the early days of the pandemic. The CDC updated its respiratory virus guidance to take a more unified approach across SARS-CoV-2, influenza, and RSV, reflecting the fact that deaths and hospitalizations from COVID-19 have declined from their peak and that more tools (vaccines, antivirals, rapid tests) are now available.²² The current framework generally recommends staying home while you have a fever and until symptoms are improving, then taking added precautions (like masking) for a few days afterward.

This guidance is a population-level compromise. It fits reasonably well with the shedding data for most healthy adults, who are clearing live virus by about the time their fever breaks and symptoms start to wane. But it doesn’t perfectly fit everyone. Children, older adults, and immunocompromised individuals may still be shedding infectious virus after meeting the standard return criteria. For people in those categories, or for those who live with someone who is, using a rapid antigen test as a supplement to calendar-based isolation is the most evidence-supported approach available.

When Positive Tests Linger After Contagiousness Ends

One source of lasting confusion is the gap between test positivity and actual contagiousness. A PCR test for SARS-CoV-2 can remain positive for weeks or even months after infection, long past the point where you pose any risk to others. The test detects fragments of viral RNA, and these fragments can linger in the respiratory tract well after the immune system has destroyed all replicating virus. RNA for the Omicron variant, for instance, was still detectable ten days after diagnosis in vaccinated individuals even though no live virus could be grown.³ For RSV, RNA clearance time in an experimental challenge study was about twelve days, roughly double the duration of actual infectious virus shedding.⁵

This distinction matters in real life. People have been kept out of work, refused boarding on flights, or isolated from family members for weeks based on a positive PCR result that reflected dead viral debris rather than a live infection. If you’re in that situation and the question is genuinely about contagiousness rather than regulatory compliance, a rapid antigen test is more informative than a PCR. A negative antigen test, taken at least a few days after symptom onset, is strong evidence that you’re no longer shedding virus that can infect someone else.

Contact Tracing Evidence on Late-Stage Spread

Some of the most reassuring evidence about the limited contagious window comes not from lab cultures but from real-world contact tracing. Two contact-tracing studies found no laboratory-confirmed onward transmission of SARS-CoV-2 when close contacts were first exposed more than five days after symptom onset in the index case.¹ In other words, even when live virus might theoretically still be present at low levels in days six through ten, the amount of virus being shed drops to a level where real-world transmission becomes very unlikely. The first few days of illness, when viral load is surging toward its peak, account for the vast majority of onward transmission.

This helps explain why household transmission studies consistently show that secondary infections within a home tend to happen early. If you’ve made it five or six days living with a sick family member without catching it, your odds of avoiding infection are quite good. It also reinforces the practical value of isolation during the first several days of symptoms, when you’re most dangerous to those around you, even if you can’t manage a full ten-day quarantine.

1
PubMed Central. The duration of infectiousness of individuals infected with SARS-CoV-2
2
PubMed Central. The New Normal: Delayed Peak SARS-CoV-2 Viral Loads Relative to Symptom Onset and Implications for COVID-19 Testing Programs
3
Emerging Infectious Diseases. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant–Infected Vaccinees
4
PubMed Central. Assessing Viral Shedding and Infectivity of Asymptomatic or Mildly Symptomatic Patients with COVID-19 in a Later Phase
5
PubMed. Viral Dynamics of the Respiratory Syncytial Virus During Experimental Human Challenge: Implication for Transmission and Protection
6
PubMed Central. Characteristics and Timing of Initial Virus Shedding in Severe Acute Respiratory Syndrome Coronavirus 2, Utah, USA
7
PubMed Central. Influenza virus shedding and symptoms: Dynamics and implications from a multi-season household transmission study
8
PubMed Central. The Timeline of Influenza Virus Shedding in Children and Adults in a Household Transmission Study of Influenza in Managua, Nicaragua
9
PubMed Central. Vaccination strategies against respiratory syncytial virus
10
PubMed Central. A Systematic Review of Prolonged SARS‐CoV‐2 Shedding in Immunocompromised Persons
11
PubMed Central. Long term SARS-CoV-2 infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection
12
PubMed Central. SARS-CoV-2 late shedding may be infectious between immunocompromised hosts
13
PubMed Central. Impact of age on duration of viral RNA shedding in patients with COVID-19
14
PubMed Central. Factors associated with prolonged viral shedding in older patients infected with Omicron BA.2.2
15
PubMed Central. Public Health Impact of Paxlovid as Treatment for COVID-19, United States
16
PubMed Central. An explanation for SARS-CoV-2 rebound after Paxlovid treatment
17
PubMed Central. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection
18
PubMed Central. The Usefulness of Antigen Testing in Predicting Contagiousness in COVID-19
19
PubMed. Identification of contagious SARS-CoV-2 infected individuals by Roche’s Rapid Antigen Test
20
PubMed Central. Airborne dispersion of droplets during coughing: a physical model of viral transmission
21
PubMed Central. Aerosol transmission of influenza A virus: a review of new studies
22
JAMA. CDC Eases Isolation Guidance for Respiratory Viruses